ACT Stock Overview
Develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
AlzChem Group AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €45.50 |
52 Week High | €48.00 |
52 Week Low | €17.55 |
Beta | 1.02 |
1 Month Change | 2.94% |
3 Month Change | 54.76% |
1 Year Change | 139.47% |
3 Year Change | 82.00% |
5 Year Change | 112.62% |
Change since IPO | 69.21% |
Recent News & Updates
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01Recent updates
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year
Aug 07Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
Jul 20Does This Valuation Of AlzChem Group AG (ETR:ACT) Imply Investors Are Overpaying?
Jul 03Shareholder Returns
ACT | DE Chemicals | DE Market | |
---|---|---|---|
7D | 3.9% | 0.5% | -0.2% |
1Y | 139.5% | 4.1% | 2.4% |
Return vs Industry: ACT exceeded the German Chemicals industry which returned 4.1% over the past year.
Return vs Market: ACT exceeded the German Market which returned 2.4% over the past year.
Price Volatility
ACT volatility | |
---|---|
ACT Average Weekly Movement | 5.6% |
Chemicals Industry Average Movement | 3.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ACT's share price has been volatile over the past 3 months.
Volatility Over Time: ACT's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1908 | 1,607 | Andreas Niedermaier | www.alzchem.com |
AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand.
AlzChem Group AG Fundamentals Summary
ACT fundamental statistics | |
---|---|
Market cap | €463.02m |
Earnings (TTM) | €39.15m |
Revenue (TTM) | €543.40m |
11.8x
P/E Ratio0.9x
P/S RatioIs ACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACT income statement (TTM) | |
---|---|
Revenue | €543.40m |
Cost of Revenue | €226.23m |
Gross Profit | €317.17m |
Other Expenses | €278.02m |
Earnings | €39.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
Earnings per share (EPS) | 3.85 |
Gross Margin | 58.37% |
Net Profit Margin | 7.20% |
Debt/Equity Ratio | 0% |
How did ACT perform over the long term?
See historical performance and comparison